Amounting to 2.2 million euros over 2 years, this latest funding from the EU Horizon 2020 Research and Innovation programme is a huge step toward clinical trials, due to start in 2020. The grant will help with regulatory safety studies and activities of Peptomyc’s first product, OMO-103, including its clinical batch production, and the design, recruitment of patients and performance of Phase I/IIa clinical trials.
Peptomyc and the laboratory of Dr. Soucek previously received an ERC Consolidator Grant and 2 separate Proof-of-Concept grants from the Horizon 2020 programme, and also an SME Instrument Phase I. These have all contributed significantly to bringing OMO-103 to its current level of development.